Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 961 to 975 of 1251 results for public health guidance

  1. ALXN1840 for treating Wilson disease [ID6422]

    In development Reference number: GID-TA11449 Expected publication date: TBC

  2. Treatments for non-small-cell lung cancer [ID6234]

    Discontinued Reference number: GID-TA11289

  3. Vimseltinib for treating tenosynovial giant cell tumours when surgery is unsuitable [TSID12099]

    In development Reference number: GID-TA11640 Expected publication date: TBC

  4. Retifanlimab with chemotherapy for untreated PD-L1-positive metastatic non-small-cell lung cancer [ID6436]

    In development Reference number: GID-TA11567 Expected publication date: TBC

  5. Evolocumab for preventing major cardiovascular events in people aged 50 to 79 at high risk who have not had a myocardial infarction or stroke [TSID11920]

    In development Reference number: GID-TA11482 Expected publication date: TBC

  6. Daprodustat for treating anaemia in people with chronic kidney disease [ID3987]

    In development Reference number: GID-TA10886 Expected publication date: TBC

  7. Generalised anxiety disorder - quetiapine [ID347]

    Discontinued Reference number: GID-TAG421

  8. Tiragolumab with atezolizumab and bevacizumab for untreated unresectable or advanced hepatocellular carcinoma [TSID12238]

    In development Reference number: GID-TA11831 Expected publication date: TBC

  9. Opicapone for adjunctive treatment of motor signs and symptoms in Parkinson's disease [TSID11941]

    In development Reference number: GID-TA11481 Expected publication date: TBC

  10. Optical Coherence Tomography to guide percutaneous coronary intervention

    In development Reference number: GID-IPG10394 Expected publication date: TBC

  11. Gefurulimab for treating antibody-positive generalised myasthenia gravis [TSID12256]

    In development Reference number: GID-TA11848 Expected publication date: TBC

  12. New life-extending treatment given the green light for people with rare form of bile duct cancer

    A new targeted treatment for a rare and aggressive form of bile duct cancer has been recommended by NICE for routine use on the NHS in England, giving people more time with better quality of life.

  13. Housing: planning to improve health and wellbeing

    Discontinued Reference number: GID-NG10053

  14. Iptacopan for treating primary IgA nephropathy [ID6640]

    In development Reference number: GID-TA11844 Expected publication date: TBC

  15. Skin abscess: antimicrobial prescribing

    Discontinued Reference number: GID-NG10163